Ignite Creation Date:
2024-05-05 @ 11:40 AM
Last Modification Date:
2024-10-26 @ 9:11 AM
Study NCT ID:
NCT00106015
Status:
RECRUITING
Last Update Posted:
2023-04-13
First Post:
2005-03-18
Brief Title:
Diamond Blackfan Anemia Registry DBAR
Sponsor:
Feinstein Institute for Medical Research
Organization:
Northwell Health
Study Overview
Official Title:
Diamond Blackfan Anemia Registry DBAR
Status:
RECRUITING
Status Verified Date:
2023-04
Last Known Status:
None
Delayed Posting:
No
If Stopped, Why?:
Not Stopped
Has Expanded Access:
False
If Expanded Access, NCT#:
N/A
Has Expanded Access, NCT# Status:
N/A
Acronym:
DBAR
Brief Summary:
The purpose of this study is to maintain a comprehensive registry of patients with the rare inherited bone marrow failure syndrome Diamond Blackfan anemia DBA
Detailed Description:
BACKGROUND
Diamond Blackfan anemia DBA is a heterogeneous genetic disorder characterized by pure red cell aplasia congenital anomalies a predisposition to pancytopenia and myelodysplasia as well as hematopoietic and non-hematopoietic cancer Anemia usually presents in infancy or early childhood and greater than 40 of patients have at least one congenital anomaly The actuarial cancer risk is as of yet undetermined One DBA gene has been cloned and the existence of at least two other DBA genes has been inferred by linkage analysis Penetrance and expressivity of DBA genes are highly variable Affected individuals within the same family may vary dramatically as to the degree of anemia response to corticosteroids the presence of congenital anomalies and the development of cancer Despite improvements in understanding of this disorder there are significant deficiencies in knowledge that inhibit the exploitation of this syndrome to increase both specific and general knowledge of mechanisms of hematopoietic failure birth defects and cancer predisposition Furthermore this disease will in the near future provide a valuable platform to study complex gene interactions There are less than 1000 individuals in the United States and Canada estimated to have DBA representing at least 11 genotypes Thus no single center follows sufficient numbers of well-characterized patients for meaningful clinical and laboratory investigations Furthermore clinicians require an accurate knowledge of the clinical and laboratory presentation mode of inheritance treatment response outcomes and prognosis to make important diagnostic treatment and reproductive decisions A comprehensive registry that captures this information and characterizes patients accurately is therefore essential to advance our understanding of DBA and in the process knowledge regarding hematopoietic cell differentiation birth defects and cancer predisposition The registry will be an essential component of clinical and laboratory DBA related research and patient care
The Diamond Blackfan Anemia Registry DBAR was established in 1992 and families were asked to participate if a member was affected by the disorder From this the Diamond Blackfan Anemia Foundation DBAF was established largely as a cooperating entity for families to share information The registry attempts to establish contact with all affected individuals at the time of diagnosis avoiding the pitfalls of reporting bias inherent to the study of many diseases for which extraordinary events prompt referral to specialized centers The registry is already capturing a high percentage of the estimated number of new cases per year and has facilitated genetic studies to define the genes responsible for the disorder Thus the registry has an established track record based on funding from non-NIH sources
The study is in response to RFA HL-04-008 on Molecular Mechanisms Underlying Diamond-Blackfan Anemia and Other Congenital Bone Marrow Failure Syndromes
DESIGN NARRATIVE
The objective of this study is to expand and update the DBAR in order to 1 facilitate investigations into the epidemiology and biology of Diamond Blackfan anemia 2 provide an accurate phenotype of DBA patients to facilitate genotype- phenotype correlations 3 provide access of well characterized patients to treatment protocols 4 provide patients to access to research studies 5 provide patients with results of research studies 6 serve as a resource to patients and their doctors to guide diagnostic therapeutic and reproductive decisions
Diamond Blackfan anemia DBA is a heterogeneous genetic disorder characterized by pure red cell aplasia congenital anomalies a predisposition to pancytopenia and myelodysplasia as well as hematopoietic and non-hematopoietic cancer Anemia usually presents in infancy or early childhood and greater than 40 of patients have at least one congenital anomaly The actuarial cancer risk is as of yet undetermined One DBA gene has been cloned and the existence of at least two other DBA genes has been inferred by linkage analysis Penetrance and expressivity of DBA genes are highly variable Affected individuals within the same family may vary dramatically as to the degree of anemia response to corticosteroids the presence of congenital anomalies and the development of cancer Despite improvements in understanding of this disorder there are significant deficiencies in knowledge that inhibit the exploitation of this syndrome to increase both specific and general knowledge of mechanisms of hematopoietic failure birth defects and cancer predisposition Furthermore this disease will in the near future provide a valuable platform to study complex gene interactions There are less than 1000 individuals in the United States and Canada estimated to have DBA representing at least 11 genotypes Thus no single center follows sufficient numbers of well-characterized patients for meaningful clinical and laboratory investigations Furthermore clinicians require an accurate knowledge of the clinical and laboratory presentation mode of inheritance treatment response outcomes and prognosis to make important diagnostic treatment and reproductive decisions A comprehensive registry that captures this information and characterizes patients accurately is therefore essential to advance our understanding of DBA and in the process knowledge regarding hematopoietic cell differentiation birth defects and cancer predisposition The registry will be an essential component of clinical and laboratory DBA related research and patient care
The Diamond Blackfan Anemia Registry DBAR was established in 1992 and families were asked to participate if a member was affected by the disorder From this the Diamond Blackfan Anemia Foundation DBAF was established largely as a cooperating entity for families to share information The registry attempts to establish contact with all affected individuals at the time of diagnosis avoiding the pitfalls of reporting bias inherent to the study of many diseases for which extraordinary events prompt referral to specialized centers The registry is already capturing a high percentage of the estimated number of new cases per year and has facilitated genetic studies to define the genes responsible for the disorder Thus the registry has an established track record based on funding from non-NIH sources
The study is in response to RFA HL-04-008 on Molecular Mechanisms Underlying Diamond-Blackfan Anemia and Other Congenital Bone Marrow Failure Syndromes
DESIGN NARRATIVE
The objective of this study is to expand and update the DBAR in order to 1 facilitate investigations into the epidemiology and biology of Diamond Blackfan anemia 2 provide an accurate phenotype of DBA patients to facilitate genotype- phenotype correlations 3 provide access of well characterized patients to treatment protocols 4 provide patients to access to research studies 5 provide patients with results of research studies 6 serve as a resource to patients and their doctors to guide diagnostic therapeutic and reproductive decisions
Study Oversight
Has Oversight DMC:
None
Is a FDA Regulated Drug?:
None
Is a FDA Regulated Device?:
None
Is an Unapproved Device?:
None
Is a PPSD?:
None
Is a US Export?:
None
Is an FDA AA801 Violation?:
None